Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Cutaneous Lupus Cases: Diagnosis, Systemic Risk, and Treatment Strategies
Description
The talk reviewed key clinical cases of cutaneous lupus and emphasized practical diagnosis, monitoring, and treatment strategies. It highlighted how discoid lupus can present with annular, scarring lesions on the face, scalp, ears, eyelids, lips, and oral mucosa, and noted that lesions may appear different in darker skin types or be subtle in hair-bearing areas. The speaker stressed assessing risk for progression to systemic lupus using history, exam, and labs: generalized skin involvement, arthralgias, non-scarring alopecia, mucosal ulcers, anemia, leukopenia, elevated inflammatory markers, high ANA, and anti-dsDNA raise concern, with greatest progression risk in the first years after diagnosis. Baseline and follow-up testing should include CBC, CMP, urinalysis, and ANA, since kidney disease may be silent; one case demonstrated asymptomatic proteinuria leading to a diagnosis of lupus nephritis despite otherwise reassuring serologies and symptoms. The talk also covered drug-induced subacute cutaneous lupus, especially from anti-TNF agents, proton pump inhibitors, and checkpoint inhibitors, and warned that mimickers such as tinea can be mistaken for refractory lupus. Treatment was presented as a stepwise ladder beginning with photoprotection, smoking cessation, topical steroids, and calcineurin inhibitors, followed by antimalarials such as hydroxychloroquine or chloroquine, with options to switch agents, add quinacrine, use brand-name Plaquenil, adjust dosing, and consider therapeutic drug monitoring to improve adherence and reduce toxicity. For more severe or refractory disease, methotrexate, mycophenolate, azathioprine, IVIG, thalidomide/lenalidomide, and newer biologics such as belimumab, anifrolumab, and possibly deucravacitinib were discussed, with anifrolumab highlighted as particularly fast and effective for skin disease.
View moreConclusions
- Cutaneous lupus can be clinically subtle and may require careful examination of hidden sites like the scalp, ears, eyelids, lips, and oral mucosa to make the diagnosis.
- Patients with cutaneous lupus need a lupus-focused review of systems and periodic laboratory monitoring, especially urinalysis, because silent systemic involvement such as nephritis can be missed without it.
- Risk of progression from cutaneous lupus to systemic lupus is higher with generalized discoid lesions, arthralgias or arthritis, alopecia, mucosal ulcers, cytopenias, elevated inflammatory markers, and positive ANA or dsDNA.
- Most patients who progress from cutaneous to systemic lupus develop mild disease, but a meaningful minority develop more severe organ-threatening involvement.
- Drug-induced subacute cutaneous lupus is common enough that a thorough medication history, including over-the-counter drugs, is essential, because it can closely mimic idiopathic SCLE.
- Not every rash in a patient with lupus is lupus, and mimickers such as tinea or other non-rheumatologic skin diseases must be considered before escalating immunosuppression.
- Basic dermatologic measures such as photoprotection, smoking cessation, and topical therapy can markedly improve cutaneous lupus, sometimes even when systemic disease is already being treated.
- Antimalarials remain first-line systemic therapy for cutaneous lupus, and switching agents, adding quinacrine, using brand-name Plaquenil, or adjusting dose can improve tolerability and adherence.
- Early hydroxychloroquine may help prevent progression to systemic disease, and therapeutic drug monitoring may help optimize dosing and identify nonadherence.
- Methotrexate and mycophenolate are useful next-line agents, with methotrexate especially helpful when joint disease is present and mycophenolate favored when kidney disease coexists.
- Biologic and newer targeted therapies are expanding options for refractory cutaneous lupus, with anifrolumab showing particularly rapid and meaningful improvement in skin disease.
- Overall, effective management of cutaneous lupus depends on combining careful diagnosis, systemic surveillance, adherence-focused monitoring, and a stepwise treatment approach tailored to disease severity and comorbidities.
- J Am Acad Dermatol 2025;93:55-63
- Arthritis Care Res (Hoboken) 2026. Feb 16.
- Bruce IN et al., Lupus Sci Med. 2023 Jan;10(1):e000761
- Morand EF et al., Lancet Rheumatol 2022 Apr;4(4):e282-92#10.1016/s2665-9913(22)00195-3
- Bokor LA et al., Autoimmun Rev. 2025 Feb 28;24(3):103723